Sanara MedTech reports preliminary FY 2025 revenue ~$103M, guides FY 2026 revenue $116M-$121M

Sanara MedTech Inc.

2025-FY EPS reported -$4.36 vs consensus $0.11 ▼ miss (-3985.9%)

Q4 2025 net revenue expected $27.2M-$27.7M, up 3-5% YoY; excluding $1.8M BIASURGE sales in Q4'24, growth 11-13%.
FY 2025 net revenue expected $102.7M-$103.2M, ~19% YoY growth; excluding $1.8M BIASURGE, growth 21-22%.
FY 2026 guidance: net revenue $116M-$121M, growth 13-17% from 2025 midpoint.
Cash $16.6M, long-term debt $46.0M at Dec 31, 2025 (vs $15.9M cash, $30.7M debt a year earlier).
BIASURGE receives Vizient Innovative Technology contract; OsStic launch planned Q1 2027 pending FDA clearance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.